{"id":"jab-3312","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"JAB-3312 targets FGFR pathways that are dysregulated in certain cancers and fibrotic diseases. By inhibiting FGFR activity, the drug aims to suppress aberrant cell proliferation and reduce pathological fibrosis. This mechanism is particularly relevant in tumors with FGFR alterations and in conditions characterized by excessive fibroblast activation.","oneSentence":"JAB-3312 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:17:37.144Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"FGFR-altered solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT04045496","phase":"PHASE1","title":"A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Jacobio Pharmaceuticals Co., Ltd.","startDate":"2019-09-26","conditions":"Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma","enrollment":40},{"nctId":"NCT04121286","phase":"PHASE1","title":"A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China","status":"COMPLETED","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2020-07-14","conditions":"Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma","enrollment":17},{"nctId":"NCT04720976","phase":"PHASE1, PHASE2","title":"JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2021-03-23","conditions":"Solid Tumor, NSCLC","enrollment":58},{"nctId":"NCT05288205","phase":"PHASE1, PHASE2","title":"Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation","status":"RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2022-04-14","conditions":"KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer","enrollment":240},{"nctId":"NCT06416410","phase":"PHASE3","title":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation","status":"RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2024-08-07","conditions":"Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer","enrollment":392}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"JAB-3312","genericName":"JAB-3312","companyName":"Allist Pharmaceuticals, Inc.","companyId":"allist-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JAB-3312 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling. Used for FGFR-altered solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}